TellBio Announces Consecutive Manuscripts Demonstrating Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Advanced Breast Cancer

TellBio, Inc., a biotechnology company focused on cancer detection, has recently published two manuscripts that highlight the applications of its TellDx platform in prostate cancer and advanced breast cancer. The publications, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cultured ful..